<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>                  1<BR>                  7<BR>                    <BR>                  PATIENT COUNSELING INFORMATION<BR>               <BR>               <BR>                  <BR>                     Information for Patients<BR>                  <BR>                  Pregnancy: Femara is contraindicated in women of premenopausal endocrine status. The physician needs to discuss the necessity of adequate contraception with women who have the potential to become pregnant including women who are perimenopausal or who recently became postmenopausal, until their postmenopausal status is fully established.<BR>                  Fatigue and Dizziness: Since fatigue and dizziness have been observed with the use of Femara and somnolence was uncommonly reported, caution is advised when driving or using machinery.<BR>                  Bone Effects: Consideration should be given to monitoring bone mineral density. <BR>                  Novartis Pharmaceuticals Corporation<BR>East Hanover, New Jersey, 07936<BR>                  © Novartis<BR>                  T2012-10<BR>                  December 2011<BR>               <BR>               <BR>            <BR>         </P></DIV></HTML>